Brief: Vascepa Found To Significantly Reduce Ischemic Events In Patients With Prior Coronary Artery Bypass Grafting Procedures
16/11/2020 12:09
Nov 16 (Reuters) - HLS Therapeutics Inc HLS.TO :
* VASCEPA® (ICOSAPENT ETHYL) FOUND TO SIGNIFICANTLY REDUCE
ISCHEMIC EVENTS IN PATIENTS WITH PRIOR CORONARY ARTERY BYPASS
GRAFTING PROCEDURES
Source text for Eikon: ID:nCNWyxhx6a
Further company coverage: HLS.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on HLS Therapeutics
See all newsBrief: Hls Therapeutics Increases Normal Course Issuer Bid
Brief: HLS Therapeutics Announces Q2 2026 Financial Results
Canada's HLS Therapeutics Q2 revenue rises on higher cardiovascular drugs demand
Brief: HLS Therapeutics - Secures Nilemdo Reimbursement With Private Payers Covering 80% Of Privately Insured Canadians
Canada Research Roundup: CIBC ,HLS Therapeutics, TD Bank Group